| Literature DB >> 32958952 |
Junichi Yamamoto1,2, Tetsufumi Suwa2, Yuki Murase2, Shumpei Tateno2, Hirotaka Mizutome2, Tomoko Asatsuma-Okumura1, Nobuyuki Shimizu1, Tsutomu Kishi3, Shuji Momose4, Masahiro Kizaki5, Takumi Ito1,6, Yuki Yamaguchi7, Hiroshi Handa8.
Abstract
The immunomodulatory drug (IMiD) thalidomide and its derivatives lenalidomide and pomalidomide are therapeutic agents used in the treatment of multiple myeloma. Although pomalidomide offers considerable clinical benefits to patients with lenalidomide-resistant multiple myeloma, the molecular mechanisms underlying its superior efficacy remain unclear. Here we show that ARID2, a component of the polybromo-associated BAF (PBAF) chromatin-remodeling complex, is a pomalidomide-induced neosubstrate of CRL4CRBN. BRD7, another subunit of PBAF, is critical for pomalidomide-induced ARID2 degradation. ARID2 is involved in transcriptional regulation of pomalidomide target genes including MYC. Pomalidomide is more effective than lenalidomide in degrading ARID2 and is capable of inhibiting MYC expression and proliferation in lenalidomide-resistant cell lines. Notably, ARID2 expression is associated with a poor prognosis and is higher in chemoresistant minimal residual disease (MRD) populations, and in patients with relapsed/refractory multiple myeloma. These findings suggest that ARID2 is a promising target for overcoming lenalidomide resistance in patients with multiple myeloma.Entities:
Mesh：
Substances：
Year: 2020 PMID： 32958952 DOI： 10.1038/s41589-020-0645-3
Source DB: PubMed Journal: Nat Chem Biol ISSN： 1552-4450 Impact factor: 15.040